blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2883546

EP2883546 - NEW DIFFERENTIAL-RELEASE PHARMACEUTICAL COMPOSITION CONTAINING THREE ACTIVE PRINCIPLES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.07.2022
Database last updated on 05.10.2024
FormerThe patent has been granted
Status updated on  06.08.2021
FormerGrant of patent is intended
Status updated on  19.04.2021
FormerExamination is in progress
Status updated on  06.01.2017
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
Landsteiner Scientific S.A. de C.V.
Av. Periférico Sur n° 4118
Torre Zafiro I
Piso 6
Colonia Jardines del Pedregal
01900 Distrito Federal / MX
[2015/25]
Inventor(s)01 / AGAPITO PERALTA, Dario
Calle Camino Real No. 27
Colonia San Antonio Buenavista
C.P. 50266 Toluca Estado de México / MX
02 / MARTÍNEZ REYES, Julián
Calle 6 Millones Mz. 85 Lt. 24
Colonia Ciudade Lago
C.P. 57180 Nezahualcoyoti Estado de México / MX
03 / REYES MORENO, Carlos Alberto
Hacienda Tejalpa No. 153
Colonia Fraccionamiento Santa Elena
C.P. 51205 Toluca Estado de México / MX
 [2015/25]
Representative(s)Covadonga Fernández-Vega Feijoo, Maria
Fernández-Vega y Asociados
Agencia de Propiedad Industrial, S.L.
C/Bréton de los Herreros, 66 - 1° B
28003 Madrid / ES
[2021/36]
Former [2015/25]Covadonga Fernández-Vega Feijoo, Maria
Fernández-Vega y Asociados
C/ Carbonero y Sol, 42 A
28006 Madrid / ES
Application number, filing date13822895.222.07.2013
[2021/36]
WO2013MX00092
Priority number, dateMX2012000854123.07.2012         Original published format: MX 2012008541
[2015/25]
Filing languageES
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014017897
Date:30.01.2014
Language:ES
[2014/05]
Type: A1 Application with search report 
No.:EP2883546
Date:17.06.2015
Language:EN
[2015/25]
Type: B1 Patent specification 
No.:EP2883546
Date:08.09.2021
Language:EN
[2021/36]
Search report(s)International search report - published on:ES30.01.2014
(Supplementary) European search report - dispatched on:EP20.04.2016
ClassificationIPC:A61K9/50, A61K9/48, A61K31/4422, A61K31/4178, A61K31/549, A61K31/435, A61P9/12
[2021/17]
CPC:
A61K31/549 (EP,US); A61K31/4178 (EP,US); A61K31/435 (EP,US);
A61K31/4422 (EP,US); A61K9/5078 (EP,US); A61P9/12 (EP)
C-Set:
A61K31/4178, A61K2300/00 (EP,US);
A61K31/4422, A61K2300/00 (US,EP);
A61K31/549, A61K2300/00 (US,EP)
Former IPC [2020/19]A61K9/50, A61K9/48, A61K31/4422, A61K31/4178, A61K31/549, A61P9/12, A61K9/16, A61K31/435
Former IPC [2015/25]A61K31/4178, A61K31/4422, A61K31/549, A61K9/24, A61P9/12
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/37]
Former [2015/25]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA23.02.2015
ME23.02.2015
TitleGerman:NEUE PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT DREI WIRKSTOFFEN MIT DIFFERENZIELLER FREISETZUNG[2015/25]
English:NEW DIFFERENTIAL-RELEASE PHARMACEUTICAL COMPOSITION CONTAINING THREE ACTIVE PRINCIPLES[2015/25]
French:NOUVELLE COMPOSITION PHARMACEUTIQUE À LIBÉRATION DIFFÉRENTIELLE CONTENANT TROIS PRINCIPES ACTIFS[2015/25]
Entry into regional phase23.02.2015Translation filed 
23.02.2015National basic fee paid 
23.02.2015Search fee paid 
24.02.2015Designation fee(s) paid 
24.02.2015Examination fee paid 
Examination proceduredeletedDeletion: Application deemed to be withdrawn, date of legal effect  [2015/25]
23.02.2015Examination requested  [2015/37]
20.03.2015Despatch of communication that the application is deemed to be withdrawn, reason: filing fee / search fee not paid in time  [2015/25]
04.07.2016Despatch of a communication from the examining division (Time limit: M06)
30.12.2016Reply to a communication from the examining division
23.04.2018Despatch of a communication from the examining division (Time limit: M06)
10.09.2018Reply to a communication from the examining division
22.11.2018Despatch of a communication from the examining division (Time limit: M04)
14.03.2019Reply to a communication from the examining division
24.01.2020Despatch of a communication from the examining division (Time limit: M02)
20.03.2020Reply to a communication from the examining division
14.04.2020Despatch of a communication from the examining division (Time limit: M06)
06.10.2020Reply to a communication from the examining division
04.11.2020Despatch of a communication from the examining division (Time limit: M04)
25.02.2021Reply to a communication from the examining division
20.04.2021Communication of intention to grant the patent
03.08.2021Fee for grant paid
03.08.2021Fee for publishing/printing paid
03.08.2021Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  04.07.2016
Opposition(s)09.06.2022No opposition filed within time limit [2022/33]
Request for further processing for:The application is deemed to be withdrawn due to non-payment of the search fee
04.05.2015Request for further processing filed
19.05.2015Decision despatched
The application is deemed to be withdrawn due to non-payment of the filing fee
04.05.2015Request for further processing filed
19.05.2015Decision despatched
The application is deemed to be withdrawn due to non-payment of the examination fee
04.05.2015Request for further processing filed
19.05.2015Decision despatched
The application is deemed to be withdrawn due to non-payment of designation fees
TR, SM, SK, SI, SE, RS, RO, PT, PL, NO, NL, MT, MK, MC, LV, LU, LT, IT, IS, IE, HU, HR, GR, GB, FR, FI, ES, EE, DK, DE, CZ, CY, CH, BG, BE, AT, AL
04.05.2015Request for further processing filed
19.05.2015Decision despatched
Fees paidRenewal fee
23.02.2015Renewal fee patent year 03
14.07.2016Renewal fee patent year 04
28.07.2017Renewal fee patent year 05
03.09.2018Renewal fee patent year 06
13.09.2019Renewal fee patent year 07
25.09.2020Renewal fee patent year 08
08.07.2021Renewal fee patent year 09
Penalty fee
Additional fee for renewal fee
31.07.201806   M06   Fee paid on   03.09.2018
31.07.201907   M06   Fee paid on   13.09.2019
31.07.202008   M06   Fee paid on   25.09.2020
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.07.2013
AL08.09.2021
AT08.09.2021
CY08.09.2021
CZ08.09.2021
DK08.09.2021
EE08.09.2021
FI08.09.2021
HR08.09.2021
LT08.09.2021
LV08.09.2021
MC08.09.2021
MK08.09.2021
MT08.09.2021
NL08.09.2021
PL08.09.2021
RO08.09.2021
RS08.09.2021
SE08.09.2021
SI08.09.2021
SK08.09.2021
SM08.09.2021
BG08.12.2021
NO08.12.2021
IS08.01.2022
PT10.01.2022
[2024/41]
Former [2024/22]HU22.07.2013
AL08.09.2021
AT08.09.2021
CY08.09.2021
CZ08.09.2021
DK08.09.2021
EE08.09.2021
FI08.09.2021
HR08.09.2021
LT08.09.2021
LV08.09.2021
MC08.09.2021
MK08.09.2021
NL08.09.2021
PL08.09.2021
RO08.09.2021
RS08.09.2021
SE08.09.2021
SI08.09.2021
SK08.09.2021
SM08.09.2021
BG08.12.2021
NO08.12.2021
IS08.01.2022
PT10.01.2022
Former [2024/20]HU22.07.2013
AL08.09.2021
AT08.09.2021
CY08.09.2021
CZ08.09.2021
DK08.09.2021
EE08.09.2021
FI08.09.2021
HR08.09.2021
LT08.09.2021
LV08.09.2021
MC08.09.2021
NL08.09.2021
PL08.09.2021
RO08.09.2021
RS08.09.2021
SE08.09.2021
SI08.09.2021
SK08.09.2021
SM08.09.2021
BG08.12.2021
NO08.12.2021
IS08.01.2022
PT10.01.2022
Former [2024/18]HU22.07.2013
AL08.09.2021
AT08.09.2021
CZ08.09.2021
DK08.09.2021
EE08.09.2021
FI08.09.2021
HR08.09.2021
LT08.09.2021
LV08.09.2021
MC08.09.2021
NL08.09.2021
PL08.09.2021
RO08.09.2021
RS08.09.2021
SE08.09.2021
SI08.09.2021
SK08.09.2021
SM08.09.2021
BG08.12.2021
NO08.12.2021
IS08.01.2022
PT10.01.2022
Former [2023/11]AL08.09.2021
AT08.09.2021
CZ08.09.2021
DK08.09.2021
EE08.09.2021
FI08.09.2021
HR08.09.2021
LT08.09.2021
LV08.09.2021
MC08.09.2021
NL08.09.2021
PL08.09.2021
RO08.09.2021
RS08.09.2021
SE08.09.2021
SI08.09.2021
SK08.09.2021
SM08.09.2021
BG08.12.2021
NO08.12.2021
IS08.01.2022
PT10.01.2022
Former [2022/36]AL08.09.2021
AT08.09.2021
CZ08.09.2021
DK08.09.2021
EE08.09.2021
FI08.09.2021
HR08.09.2021
LT08.09.2021
LV08.09.2021
NL08.09.2021
PL08.09.2021
RO08.09.2021
RS08.09.2021
SE08.09.2021
SI08.09.2021
SK08.09.2021
SM08.09.2021
BG08.12.2021
NO08.12.2021
IS08.01.2022
PT10.01.2022
Former [2022/29]AL08.09.2021
AT08.09.2021
CZ08.09.2021
EE08.09.2021
FI08.09.2021
HR08.09.2021
LT08.09.2021
LV08.09.2021
NL08.09.2021
PL08.09.2021
RO08.09.2021
RS08.09.2021
SE08.09.2021
SK08.09.2021
SM08.09.2021
BG08.12.2021
NO08.12.2021
IS08.01.2022
PT10.01.2022
Former [2022/25]AT08.09.2021
CZ08.09.2021
EE08.09.2021
FI08.09.2021
HR08.09.2021
LT08.09.2021
LV08.09.2021
NL08.09.2021
PL08.09.2021
RO08.09.2021
RS08.09.2021
SE08.09.2021
SK08.09.2021
SM08.09.2021
BG08.12.2021
NO08.12.2021
IS08.01.2022
PT10.01.2022
Former [2022/24]AT08.09.2021
CZ08.09.2021
EE08.09.2021
FI08.09.2021
HR08.09.2021
LT08.09.2021
LV08.09.2021
NL08.09.2021
PL08.09.2021
RO08.09.2021
RS08.09.2021
SE08.09.2021
SK08.09.2021
BG08.12.2021
NO08.12.2021
IS08.01.2022
PT10.01.2022
Former [2022/23]AT08.09.2021
CZ08.09.2021
EE08.09.2021
FI08.09.2021
HR08.09.2021
LT08.09.2021
LV08.09.2021
PL08.09.2021
RS08.09.2021
SE08.09.2021
SK08.09.2021
BG08.12.2021
NO08.12.2021
PT10.01.2022
Former [2022/21]AT08.09.2021
FI08.09.2021
HR08.09.2021
LT08.09.2021
LV08.09.2021
RS08.09.2021
SE08.09.2021
BG08.12.2021
NO08.12.2021
Former [2022/10]FI08.09.2021
HR08.09.2021
LT08.09.2021
LV08.09.2021
RS08.09.2021
SE08.09.2021
BG08.12.2021
NO08.12.2021
Former [2022/09]FI08.09.2021
LT08.09.2021
RS08.09.2021
SE08.09.2021
BG08.12.2021
NO08.12.2021
Former [2022/08]FI08.09.2021
LT08.09.2021
SE08.09.2021
BG08.12.2021
NO08.12.2021
Former [2022/07]LT08.09.2021
NO08.12.2021
Documents cited:Search[I]  - Karunanidhi, "Simultaneous Analysis of Losartan Potassium, Amlodipine Besylate, and Hydrochlorothiazide in Bulk and in Tablets by High-Performance Thin Layer Chromatography with UV-Absorption Densitometry", J Anal Methods Chem, (20120408), pages 1 - 10, URL: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335319/, (20160412), XP055264827 [I] 1-10 * point 2.2 *
International search[X]US2010143470  (KIM SUNG WUK [KR], et al);
 [X]US2010047341  (KIM SUNG WUK [KR], et al);
 [X]KR20090131472  ;
 [A]WO03097045  (NOVARTIS AG [CH], et al);
 [A]WO2009134956  (BLUE NOTE PHARMACEUTICALS INC)
 [X]  - DATABASE WPI, 1, Derwent World Patents Index, Database accession no. 2010-A38512, XP055190227 & KR20090131472 A 20091229 (SAM CHUN DANG PHARM CO LTD)
by applicantWO2012055941
 MX2008016532
 MX198140
    - FOGARI R; ZOPPI A; DEROSA G; MUGELLINI A; LAZZARI P; RINALDI A ET AL., "Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients", J HUM HYPERTENS, (2007), vol. 21, pages 220 - 4
    - MESSERLI FH., "Vasodilatory edema: a common side effect of antihypertensive therapy", CURR CARDIOL REPORTS, (2002), vol. 4, pages 479 - 82, XP009034237
    - CALHOUN DA; LACOURCIERE T; CHIANG YT; GLAZER RD, TRIPLE ANTIHYPERTENSIVE THERAPY WITH AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE: A RANDOMIZED CLINICAL TRIAL
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.